You can buy or sell HARP and other stocks, options, ETFs, and crypto commission-free!
Harpoon Therapeutics, Inc. Common Stock, also called Harpoon Therapeutics, is a clinical-stage immunotherapy company, which develops a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. Read More T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTACs) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. The company was founded by Patrick A. Baeuerle, Luke B. Evnin, and Jeanmarie Guenot on March 19, 2015 and is headquartered in South San Francisco, CA.
South San Francisco, California
52 Week High
52 Week Low
— per share
Expected Nov 5, After Hours